PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Short Interest Down 40.7% in July

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 14,700 shares, a decrease of 40.7% from the June 30th total of 24,800 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 17,200 shares, the short-interest ratio is currently 0.9 days.

Institutional Investors Weigh In On PharmaCyte Biotech

A hedge fund recently raised its stake in PharmaCyte Biotech stock. K2 Principal Fund L.P. raised its position in shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCB) by 17.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 304,613 shares of the company’s stock after buying an additional 46,132 shares during the period. K2 Principal Fund L.P. owned about 3.53% of PharmaCyte Biotech worth $655,000 at the end of the most recent reporting period. 34.24% of the stock is currently owned by institutional investors.

PharmaCyte Biotech Stock Down 1.9 %

Shares of PharmaCyte Biotech stock traded down $0.04 during trading on Friday, reaching $1.98. The company’s stock had a trading volume of 1,735 shares, compared to its average volume of 21,253. PharmaCyte Biotech has a 52-week low of $1.76 and a 52-week high of $2.82. The company has a market cap of $16.74 million, a price-to-earnings ratio of -1.65 and a beta of -0.19. The firm’s 50-day moving average is $2.07 and its two-hundred day moving average is $2.14.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.